respiratory disease
News/ News/ R&D/ Top stories
AstraZeneca’s respiratory biologic fails again in COPD
Linda Banks
AZ, COPD, Fasenra, MedImmune, respiratory biologic, respiratory disease
0 Comment
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.
X
AstraZeneca’s respiratory biologic fails again in COPD
https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/